Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Cancer Prev Res (Phila). 2021 Jul 15;14(9):851–862. doi: 10.1158/1940-6207.CAPR-20-0496

Figure 2. Effect of sulindac and bexarotene in FAP patient-derived organoids.

Figure 2.

The line graph represents the IC50 calculations from (A) sulindac and (B) bexarotene treatment of colonic organoids derived from FAP patients; (C) Cell viability of FAP colon organoids following combined treatment with sulindac and bexarotene; (D) Organoids derived from the colon of normal and polyp tissue from FAP patients at MD Anderson and seeded in Matrigel. Images were captured 48 hours after treatment at 4X magnification.